ANGIODYNAMICS INC
No enriched coverage for $ANGO in the last 7 days.
AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.
Biotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.
Nighan Warren JR (SVP Quality and Regulatory) sold 23,370 shares of ANGIODYNAMICS INC (ANGO) at $14.72 ($0.34M total) on 2026-07-30.
Recent ANGO coverage spans financial news, earnings and sector analysis.
In the last 30 days, ANGO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($344K). The most active reporter was Nighan Warren JR, SVP Quality and Regulatory, with 1 filing.
Guidance and reimbursement/clinical program updates support a constructive medium-term view, but timing uncertainty around trials and FDA discussions limits near-term conviction.
Near-term momentum is tied to FDA-cleared study activity and reported trial positivity, which can re-rate clinical probability and sentiment.
Routine insider open-market sale with no 10b5-1 plan disclosed; likely limited incremental signal for near-term fundamentals.
Earnings call provides fresh quarterly datapoints and forward-looking clinical/regulatory catalysts (IDE approvals) that can re-rate near-term growth expectations.
Call highlights suggest incremental commercialization momentum for NanoKnife, but with no new quantified guidance or financial datapoints beyond cadence expectations.
alphai scores every news story that mentions ANGO with an AI model for sentiment and relevance, and aggregates insider trades from ANGIODYNAMICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.
4 min readBiotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.
7 min readNighan Warren JR (SVP Quality and Regulatory) sold 23,370 shares of ANGIODYNAMICS INC (ANGO) at $14.72 ($0.34M total) on 2026-07-30.
2 min readAngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.
7 min readAngioDynamics (ANGO) discussed Q4 2026 earnings call topics including Palmetto LCD adoption progress, ongoing work on consistent reimbursement, and NanoKnife interest tied to Medicare coverage. Management said BPH is larger than prostate cancer but market size is not quantified. Mechanical thrombectomy revenue declined amid competition and internal commercial changes. Q4 is expected to be highest for revenue and cash generation.
6 min readANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20077916_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability Delivered its seventh consecutive quarter of double-digit
6 min readPoint72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a beneficial ownership of 3,181,829 shares in AngioDynamics (ANGO), representing a 7.7% stake as of March 31, 2026. These shares are held through Point72 Associates, an investment fund managed by Point72 Asset Management, and involve shared voting and dispositive power. The filing clarifies the control relationships among the reporting entities, with Steven A. Cohen controlling both Point72 Asset Management and Point72 Capital Advisors Inc., but explicitly states that the reporting persons do not directly own these shares.
3 min readAngioDynamics (NASDAQ: ANGO) President and CEO, Jim Clemmer, will present at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 1:40 p.m. ET. A live webcast of the presentation will be available on the company's website. AngioDynamics specializes in medical technology for vascular systems, cancer treatment, and patient quality of life.
2 min readAngioDynamics Inc. (ANGO) reported a fiscal second-quarter loss of $6.4 million, or 15 cents per share, adjusting to less than 1 cent per share for specific costs. The medical device maker announced revenue of $79.4 million and anticipates full-year losses between 23 to 33 cents per share, with revenue guidance of $312 million to $314 million. Its shares have grown 3% year-to-date and 46% over the past 12 months.
2 min readAngioDynamics, Inc. ( NASDAQ:ANGO ) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.
3 min read
